Seeking HIV treatment clues in the neem tree

Seeking HIV treatment clues in the neem tree

Soy protein alleviates symptoms of fatty liver disease, study suggests

In continuation of my update on Soy

Soy protein alleviates symptoms of fatty liver disease, study suggests

Forty-year-old Fourier transform mass spectrometry phasing problem solved

Forty-year-old Fourier transform mass spectrometry phasing problem solved: Scientists have developed a computation which simultaneously doubles the resolution, sensitivity and mass accuracy of Fourier Transform Mass Spectrometry (FTMS) at no extra cost.

Liquorice root found to contain anti-diabetic substance

In continuation of my update on Liquorice roots

Liquorice root found to contain anti-diabetic substance

Omega-3 fatty acids may help to reduce the physical harm caused by smoking

In continuation of my update on Omega-3-fatty acids...

Omega-3 fatty acids may help to reduce the physical harm caused by smoking: Omega-3 fatty acids may help to reduce the physical harm caused by smoking, according to a new study.

Experts share top 5 springtime fruits and vegetables that fight cancer

Experts share top 5 springtime fruits and vegetables that fight cancer: The price of springtime fruits and vegetables seems to increase each year. But when buyers break this expense down to cents, they realize stocking up on these cancer-fighting foods still makes economical sense, say experts from The University of Texas MD Anderson Cancer Center.

EMA CHMP recommends approval of AMAG’s ferumoxytol

EMA CHMP recommends approval of AMAG’s ferumoxytol: AMAG Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron therapy, for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

More info on Ferumoxytol : http://www.druginformation.com/RxDrugs/F/Ferumoxytol%20Injection.html

Consumption of long-chain omega-3 PUFAs lowers risk of colorectal polyps in women

In continuation of my update on omega fatty acids

Consumption of long-chain omega-3 PUFAs lowers risk of colorectal polyps in women: New research finds that omega-3 polyunsaturated fatty acids (PUFAs) found in seafood (long-chain omega-3s) may reduce the risk of precancerous colorectal polyps in women, enhance the muscular benefits of strength training in older women and improve eye health after corneal surgery.

Natural products isolated from marine mollusks and sponges can reverse multidrug resistance in cancer cells

Oceans are a treasure trove of naturally produced chemical compounds with impressive and varied biological activity. One class of these compounds, the lamellarins, has some members that are cytotoxic, while others are able to reverse multidrug resistance in certain cancer cells. These lamellarins (see below structure) act by inhibiting the so-called P-glycoprotein, which enhances transport of anticancer agents out of cancer cells, thus rendering the cells multidrug resistant.

Now researchers lead by Professor Rob Capon, have set out to determine the structures of a variety of lamellarins and correlate them to the activity of the compounds. As they report in Chemistry—An Asian Journal, the activity is not determined by the core structure of the compounds but rather depends on the exact nature of pendant groups adorning the periphery of the molecule. Those compounds in which many hydroxy (OH) groups had been replaced with methoxy (OCH₃) were able to reverse multidrug resistance in human colon cancer cells, while those featuring a large number of hydroxy groups showed higher cytotoxic activity.

Natural products such as the lamellarins are often valued for their cytotoxic properties for use as anticancer drugs. Capon, however, comments, "Our investigation reaffirms the view that non-cytotoxic natural products can exhibit valuable biological properties that allude to both an ecological advantage and a pharmacological potential....

Ref : http://onlinelibrary.wiley.com/doi/10.1002/asia.201101049/abstract;jsessionid=D96AD6C21A9E2EAF7D966C0743768A2A.d01t03

Coffee's Unique Health Benefits........

In continuation of my update on coffee, 

 

• Coffee is the greatest source of antioxidants in the American diet.3,4 And the good news is that sound scientific studies have found that the common fears about excess coffee consumption are invalid, and higher intake means bigger benefits. 
• An impressive number of studies have shown a strong association between higher consumption of coffee and a significantly reduced risk of most chronic diseases, including diabetes, cardiovascular disease, cancer, Alzheimer's disease, and others.
• With over 1,000 phytochemicals, coffee's unparalleled antioxidant punch no doubt plays a role in its protection against disease. But a multitude of direct biological actions on the body are suspected, such as an improvement in intracellular signaling,95,96 which may help prevent cancer, diabetes and more.
• Drinking just one cup of coffee a day - caffeinated or decaffeinated - can decrease the risk of developing diabetes by 13%.24 But at 12 cups a day, the risk of getting diabetes is slashed by 67%.21
• Far from being a risky habit, coffee has now been shown to provide powerful protection against an epidemic of diabetes and a rising tide of other age-related diseases. It's an all-natural and inexpensive elixir - to go!

 While I wanted to compile all the benefits of coffee in one article, I found a detailed article and many interesting ones at  Life Extension Magazine.  

At the same I was impressed with A graphic on coffee- How  Coffee Revolutionized the world !. It gives an idea about how the coffee revolutionized the world since 800 AD to 2012, well done Tony Shin.. 

Neupro Approved by U.S. FDA for Parkinson's Disease and Restless Legs Syndrome

 We know that, Rotigotine (see below structure, Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.

 

Neupro Approved by U.S. FDA for Parkinson's Disease and Restless Legs Syndrome:  UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic...

Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia

 In continuation of my update on Liraglutide

Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia:  Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza (liraglutide [rDNA origin] injection) to include data showing superior blood...

Weight loss pill Qnexa wins panel vote and awaits approval

We know that, The combination of the drugs phentermine (see structure-1) and topiramate (structure -2) (trade name Qnexa) is an investigational medication for the treatment ofobesity and related conditions such as type 2 diabetes and has been found to lower blood pressure and cholesterol.  Qnexa is being developed by Vivus, a California pharmaceutical company.  Phentermine is an appetite suppressant and stimulant of the amphetamine andphenethylamine class. Topiramate is an anticonvulsant that has weight loss side effects.

Structure 1

Structure-2

       

Weight loss pill Qnexa wins panel vote and awaits approval: The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.

                                                                                                                       

Sucampo announces positive results from lubiprostone phase 3 trial on OBD

We know that, Lubiprostone (rINN, marketed under the trade name Amitiza) is a medication used in the management of chronic idiopathicconstipation and irritable bowel syndrome. It was approved by the U.S. Food and Drug Administration (FDA) for this purpose on 31 January 2006.

Sucampo announces positive results from lubiprostone phase 3 trial on OBD: Sucampo Pharmaceuticals, Inc. today announced positive top-line results from an open-label phase 3 clinical trial designed to evaluate the long-term safety and efficacy of lubiprostone in opioid-induced bowel dysfunction (OBD) patients with chronic, non-cancer-related pain.

Metformin may protect against liver cancer

In continuation of my update on Metformin

Metformin may protect against liver cancer: Metformin, a widely used, well-tolerated drug prescribed for patients with diabetes, may protect against liver cancer, according to a new study.